P2RX7 and neoplasm: However, even in P2X7 null-hosts, when an implanted tumor expresses P2X7, the administration of P2X7 antagonists causes a significant reduction in neoplastic growth accompanied by a substantial increase in CD4+ infiltrates, and also a decrease in the expression of the fitness marker CD73 in Tregs [15].